BMS and Clovis to initiate Phase II and III combination trials for oncology

Bristol-Myers Squibb (BMS) has signed a clinical collaboration agreement to investigate the combination of its Opdivo (nivolumab) with Clovis Oncology ’s Rubraca in a Phase II and two Phase III clinical trials to treat various types of tumours.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news